Search

Your search keyword '"Kos Kudla, B"' showing total 13 results
Start Over Author "Kos Kudla, B" Topic medicine.medical_specialty
13 results on '"Kos Kudla, B"'

1. Unmet Needs in Appendiceal Neuroendocrine Neoplasms

Author

Toumpanakis, C, Fazio, N, Janson, ET, Horsch, D, Pascher, A, Reed, N, O'Toole, D, van Dijkum, EN, Partelli, S, Rinke, A, Kos-Kudla, B, Costa, F, Pape, UF, Grozinsky-Glasberg, S, Scoazec, JY, Detlef, B, Rudolf, A, Eric, B, Lisa, B, Ivan, B, Jaume, C, Martyn, C, Jie, C, Frederico, C, Anne, C, Jaroslaw, BC, de Herder, W.W., Massimo, F, Jenny, F, Nicola, F, Diego, F, Andrea, F, Rocio, GC, Simona, G, Vera, G, Ashley, G, Dieter, H, Robert, J, Gregory, K, Gunter, K, Peter, KU, Beata, KK, Guenter, JK, Krenning, EP, Matthew, K, Steven, WJL, Elisabeth, NV, Manuel, OJ, Dermot, O, Ulrich-Frank, P, Di Stefano, P, Ellen, PM, Marc, P, John, R, Nicholas, R, Guido, R, Anja, R, Philippe, R, Halfdan, S, Anders, S, Jean-Yves, S, Babs, GT, Eva, TJ, Christos, T, Juan, V, Marie-Pierre, V, Staffan, W, Bertram, W, Internal Medicine, ENETS 2016 Munich Advisory Board, Toumpanakis, C., Fazio, N., Tiensuu Janson, E., Horsch, D., Pascher, A., Reed, N., O'Apostoole, D., Nieveen Van Dijkum, E., Partelli, S., Rinke, A., Kos-Kudla, B., Costa, F., Pape, U. -F., Grozinsky-Glasberg, S., and Scoazec, J. -Y.

Subjects
medicine.medical_specialty, Biomedical Research, Critical approach, Neuroendocrine Tumors/diagnosis, Endocrinology, Diabetes and Metabolism, Guidelines as Topic, 030209 endocrinology & metabolism, Aggressive disease, Appendix, 030218 nuclear medicine & medical imaging, Unmet needs, Biomedical Research/trends, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Endocrinology, Internal medicine, Epidemiology, medicine, Humans, Intensive care medicine, Appendiceal neuroendocrine neoplasm, Appendiceal Neoplasms/diagnosis, Endocrine and Autonomic Systems, business.industry, Clinical course, Right hemicolectomy, Retrospective cohort study, Prognosis, Carcinoid, Neuroendocrine tumour, Neuroendocrine Tumors, Appendiceal Neoplasms, Human medicine, Appendicectomy, business
Abstract

Appendiceal neuroendocrine neoplasms (ANEN) are mostly discovered coincidentally during appendicectomy and usually have a benign clinical course; thus, appendicectomy alone is considered curative. However, in some cases, a malignant potential is suspected, and therefore additional operations such as completion right hemicolectomy are considered. The existing European Neuroendocrine Tumour Society (ENETS) guidelines provide useful data about epidemiology and prognosis, as well as practical recommendations with regards to the risk factors for a more aggressive disease course and the indications for a secondary operation. However, these guidelines are based on heterogeneous and retrospective studies. Therefore, the evidence does not seem to be robust, and there are still unmet needs in terms of accurate epidemiology and overall prognosis, optimal diagnostic and follow-up strategy, as well as identified risk factors that would indicate a more aggressive surgical approach at the beginning and a more intense follow-up. In this review, we are adopting a critical approach of the ENETS guidelines and published series for ANEN, focusing on the above-noted “grey areas”.

Published
2019

2. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers

Author

O'Toole, D., Grossman, A., Gross, D., Fave, G. D., Barkmanova, J., O'Connor, J., Pape, U. F., Plöckinger, U., Åkerström, G., Annibale, B., Arnold, R., Bajetta, E., Chen, Y. J., Costa, F., Couvelard, A., Davar, J., Herder, W. D., Eriksson, B., Falconi, M., Ferone, D., Gustafsson, B., Hyrdel, R., Ivan, D., Kaltsas, G., Kianmanesh, R., Klöppel, G., Knigge, U. P., Komminoth, P., Kos Kudla, B., Kwekkeboom, D., Lebtahi, R., Lewington, V., Mcnicol, A. M., Mitry, E., Nilsson, O., Öberg, K., Papotti, M., Pavel, M., Perren, A., Platania, M., Rindi, G., Ruszniewski, P., Salazar, R., Scarpa, Aldo, Scheidhauer, K., Scoazec, J. Y., Sundin, A., Szpak, W., Taal, B., Vitek, P., Vullierme, M. P., and Wiedenmann, B.

Subjects
Endocrinology, Diabetes and Metabolism, Diagnostic accuracy, insulinoma, Neuroendocrine tumors, Bioinformatics, secretin, 0302 clinical medicine, Endocrinology, immune system diseases, cancer diagnosis, conference paper, Biochemical markers, biology, Urinary 5-hydroxyindoleacetic acid, Chromogranin A, Fasting, Hydroxyindoleacetic Acid, Diabetes and Metabolism, Neuroendocrine Tumors, priority journal, 030220 oncology & carcinogenesis, diagnostic accuracy, 5 hydroxyindoleacetic acid, neuroendocrine tumor, hormones, hormone substitutes, and hormone antagonists, Neuroendocrine tumor test, musculoskeletal diseases, medicine.medical_specialty, Standard of care, MEDLINE, 610 Medicine & health, 030209 endocrinology & metabolism, 03 medical and health sciences, Cellular and Molecular Neuroscience, Patient information, Internal medicine, gastrin, medicine, Humans, biochemistry, human, Insulinoma, Gastrinoma, gastrinoma, Endocrine and Autonomic Systems, business.industry, practice guideline, biochemical marker, chromogranin A, hypoglycemia, patient information, medicine.disease, body regions, biology.protein, 570 Life sciences, Biomarkers, business
Abstract

Biomarkers have been the mainstay in the diagnosis and follow-up of patients with neuroendocrine tumors (NETs) over the last few decades. In the beginning, secretory products from a variety of subtypes of NETs were regarded as biomarkers to follow during diagnosis and treatment: serotonin for small intestinal (SI) NETs, and gastrin and insulin for pancreatic NETs. However, it became evident that a large number of NETs were so-called nonfunctioning tumors without secreting substances that caused hormone-related symptoms. Therefore, it was necessary to develop so-called “general tumor markers.” The most important ones so far have been chromogranin A and neuron-specific enolase (NSE). Chromogranin A is the most important general biomarker for most NETs with a sensitivity and specificity somewhere between 60 and 90%. NSE has been a relevant biomarker for patients with high-grade tumors, particularly lung and gastrointestinal tract tumors. Serotonin and the breakdown product urinary 5-hydroxyindoleacetic acid (U-5-HIAA) is still an important marker for diagnosing and follow-up of SI NETs. Recently, 5-HIAA in plasma has been analyzed by high-performance liquid chromatography and fluorometric detection and has shown good agreement with U-5-HIAA analysis. In the future, we will see new tests including circulating tumor cells, circulating DNA and mRNA. Recently, a NET test has been developed analyzing gene transcripts in circulating blood. Preliminary data indicate high sensitivity and specificity for NETs. However, its precise role has to be validated in prospective randomized controlled trials which are ongoing right now.

Published
2017
Full Text
View/download PDF

3. Unmet medical needs in metastatic lung and digestive neuroendocrine neoplasms

Author

Capdevila, Jaume, Bodei, Lisa, Davies, Philippa, Gorbounova, Vera, Jensen, Robert T., Knigge, Ulrich P., Krejs, Guenter J., Krenning, Eric, O'Connor, Juan Manuel, Peeters, Marc, Rindi, Guido, Salazar, Ramon, Vullierme, Marie-Pierre, Pavel, Marianne E., Arnold, R., Bartsch, D., Baudin, E., Bodei, L., Borbath, I, Capdevila, J., Caplin, M., Chen, J., Costa, F., Couvelard, A., Cwikla, J. B., Davies, P., de Herder, W. W., Falconi, M., Falkerby, J., Fazio, N., Ferone, D., Frilling, A., Garcia-Carbonero, R., Glasberg, S., Gorbunova, V, Grossman, A., Hoersch, D., Jensen, R. T., Kaltsas, G., Kloeppel, G., Knigge, U. P., Kos-Kudla, B., Krejs, G. J., Krenning, E., Kulke, M., Lamberts, S. W. J., van Dijkum, Nieveen E., O'Connor, J. M., O'Toole, D., Pape, U. F., Partelli, S., Pavel, M. E., Ramage, J., Reed, N. Simon Beatson, Rindi, G., Rinke, A., Ruszniewski, P., Sorbye, H., Sundin, A., Scoazec, J. Y., Taal, B. G., Tiensuu, J. E., Toumpanakis, C., Valle, J., Vullierme, M. P., Welin, S., Wiedenmann, B., Capdevila, J, Bodei, L, Davies, P, Gorbounova, V, Jensen, Rt, Knigge, Up, Krejs, Gj, Krenning, E, O'Connor, Jm, Peeters, M, Rindi, G, Salazar, R, Vullierme, Mp, Pavel, Me, on behalf the ENETS 2016 Munich Advisory Board, Participant, Partelli, S, Falconi, M, Erasmus MC other, Internal Medicine, ENETS 2016 Munich Advisory Board, and Dr. Heinz-Horst Deichmann Stiftung

Subjects
Biomedical Research, Lung Neoplasms, Endocrinology, Diabetes and Metabolism, Metastasi, Lanreotide, Digestive System Neoplasms, Metastasis, 030218 nuclear medicine & medical imaging, Imaging, chemistry.chemical_compound, EVEROLIMUS, 0302 clinical medicine, Endocrinology, LANREOTIDE, Treatment options, TUMORS, Clinical Practice, Neuroendocrine Tumors, Unmet medical needs, SURVIVAL, ENETS 2016 Munich Advisory Board Participants, Life Sciences & Biomedicine, medicine.medical_specialty, 030209 endocrinology & metabolism, SUNITINIB, Endocrinology & Metabolism, 03 medical and health sciences, Cellular and Molecular Neuroscience, Drug Development, Internal medicine, medicine, Biomarkers, Tumor, Humans, Limited evidence, Intensive care medicine, Science & Technology, Endocrine and Autonomic Systems, business.industry, Neurosciences, 1103 Clinical Sciences, Biomarker, Neuroendocrine neoplasm, chemistry, Neuroendocrine neoplasms, Neurosciences & Neurology, Human medicine, Therapy, 1109 Neurosciences, business, Who classification, Biomarkers
Abstract

Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.

Published
2019

4. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms

Author

Fave, G. D., Kwekkeboom, D. J., Cutsem, E. V., Rindi, G., Kos Kudla, B., Knigge, U., Sasano, H., Tomassetti, P., Salazar, R., Ruszniewski, P., Conference Anlauf M, B. C., Arnold, R, Bartsch, D, Baudin, E, Baum, R, Brandi, Ml, Cadiot, G, Costa, F, Caplin, M, Couvelard, A, de Herder, W, Delle Fave, G, Denecke, T, Eriksson, B, Falconi, Massimo, Gress, T, Gross, D, Grossman, A, Jensen, R, Kaltsas, G, Kelestimur, F, Kianmanesh, R, Klöppel, G, Klose, Kj, Knigge, U, Komminoth, P, Kos Kudla, B, Krenning, E, Kwekkeboom, D, Lopes, Jm, Niederle, B, Nilsson, O, Öberg, K, O'Connor, J, O'Toole, D, Pape, Uf, Papotti, M, Pascher, A, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Salazar, R, Sasano, H, Sauvanet, A, Scoazec, Jy, Steinmüller, T, Sundin, A, Taal, B, Tomassetti, P, Van Cutsem, E, Vullierme, Mp, Wiedenmann, B., Fave, G. D., Kwekkeboom, D. J., Cutsem, E. V., Rindi, G., Kos Kudla, B., Knigge, U., Sasano, H., Tomassetti, P., Salazar, R., Ruszniewski, P., Radiology & Nuclear Medicine, Delle Fave G., Kwekkeboom DJ., Van Cutsem E., Rindi G., Kos-Kudla B., Knigge U., Sasano H., Tomassetti P., Salazar R., and Ruszniewski P.

Subjects
medicine.medical_specialty, Settore MED/06 - ONCOLOGIA MEDICA, Endocrine and Autonomic Systems, business.industry, Endocrinology, Diabetes and Metabolism, MEDLINE, diagnosis/epidemiology/therapy, GUIDELINES, University hospital, ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms, Cellular and Molecular Neuroscience, Neuroendocrine Tumors, Endocrinology, Duodenal Neoplasms, diagnosis/epidemiology/therapy, Humans, Neuroendocrine Tumors, diagnosis/epidemiology/therapy, Stomach Neoplasms, Stomach Neoplasms, Internal medicine, medicine, Humans, business
Abstract

a Department of Digestive and Liver Disease, Ospedale Sant’Andrea, Rome , Italy; b Department of Oncology, Royal Free University UFR Bichat-Beaujon-Louis Mourier, Colombes , France; c Digestive Oncology, University Hospital Gasthuisberg/Leuven, Leuven , Belgium; d Institute of Pathology, Catholic University – Policlinic A. Gemelli, Rome , Italy; e Department of Endocrinology, Medical University of Silesia, Katowice , Poland; f Department of Surgery, Rigshospitalet, Copenhagen University Hospital, Copenhagen , Denmark; g Department of Pathology, Tohoku University Graduate School of Medicine, Sendai , Japan; h Department of Internal Medicine and Gastroenterology, St. Orsola Hospital, University of Bologna, Bologna , Italy; i Institut Catala d’Oncologia (IDIBELL), Barcelona , Spain; j Department of Gastroenterology, Beaujon Hospital, Clichy , France

Published
2012

5. ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary

Author

M. Pavel, E. Baudin, A. Couvelard, E. Krenning, K. Öberg, T. Steinmüller, M. Anlauf, B. Wiedenmann, R. Salazar, B. C. Conference Anlauf M, Arnold R, Bartsch D, Baudin E, Baum R, Brandi ML, Cadiot G, Costa F, Caplin M, Couvelard A, de Herder W, Delle Fave G, Denecke T, Eriksson B, Gress T, Gross D, Grossman A, Jensen R, Kaltsas G, Kelestimur F, Kianmanesh R, Klöppel G, Klose KJ, Knigge U, Komminoth P, Kos Kudla B, Krenning E, Kwekkeboom D, Lopes JM, Niederle B, Nilsson O, Öberg K, O'Connor J, O'Toole D, Pape UF, Papotti M, Pascher A, Pavel M, Perren A, Plöckinger U, Rindi G, Ruszniewski P, Salazar R, Sasano H, Sauvanet A, Scoazec JY, Steinmüller T, Sundin A, Taal B, Tomassetti P, Van Cutsem E, Vullierme MP, Wiedenmann B., FALCONI , MASSIMO, M., Pavel, E., Baudin, A., Couvelard, E., Krenning, K., Öberg, T., Steinmüller, M., Anlauf, B., Wiedenmann, R., Salazar, B. C., Conference Anlauf M, Arnold, R, Bartsch, D, Baudin, E, Baum, R, Brandi, Ml, Cadiot, G, Costa, F, Caplin, M, Couvelard, A, de Herder, W, Delle Fave, G, Denecke, T, Eriksson, B, Falconi, Massimo, Gress, T, Gross, D, Grossman, A, Jensen, R, Kaltsas, G, Kelestimur, F, Kianmanesh, R, Klöppel, G, Klose, Kj, Knigge, U, Komminoth, P, Kos Kudla, B, Krenning, E, Kwekkeboom, D, Lopes, Jm, Niederle, B, Nilsson, O, Öberg, K, O'Connor, J, O'Toole, D, Pape, Uf, Papotti, M, Pascher, A, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Salazar, R, Sasano, H, Sauvanet, A, Scoazec, Jy, Steinmüller, T, Sundin, A, Taal, B, Tomassetti, P, Van Cutsem, E, Vullierme, Mp, Wiedenmann, B., and Radiology & Nuclear Medicine

Subjects
medicine.medical_specialty, animal structures, Endocrinology, Diabetes and Metabolism, Intestinal Neoplasm, Neuroendocrine tumors, Biology, digestive system, Cellular and Molecular Neuroscience, Endocrinology, stomatognathic system, Internal medicine, Intestinal Neoplasms, medicine, Humans, Endocrine and Autonomic Systems, Liver Neoplasms, fungi, Midgut, Hindgut, Foregut, medicine.disease, Neuroendocrine Tumors, embryonic structures, Unknown primary, Neoplasms, Unknown Primary
Abstract

ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary

Published
2012
Full Text
View/download PDF

6. ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas

Author

U. Pape, A. Perren, B. Niederle, D. Gross, T. Gress, F. Costa, R. Arnold, T. Denecke, U. Plöckinger, R. Salazar, A. Grossman, B. C. Conference Anlauf M, Arnold R, Bartsch D, Baudin E, Baum R, Brandi ML, Cadiot G, Costa F, Caplin M, Couvelard A, de Herder W, Delle Fave G, Denecke T, Eriksson B, Gress T, Gross D, Grossman A, Jensen R, Kaltsas G, Kelestimur F, Kianmanesh R, Klöppel G, Klose KJ, Knigge U, Komminoth P, Kos Kudla B, Krenning E, Kwekkeboom D, Lopes JM, Niederle B, Nilsson O, Öberg K, O'Connor J, O'Toole D, Pape UF, Papotti M, Pascher A, Pavel M, Perren A, Plöckinger U, Rindi G, Ruszniewski P, Salazar R, Sasano H, Sauvanet A, Scoazec JY, Steinmüller T, Sundin A, Taal B, Tomassetti P, Van Cutsem E, Vullierme MP, Wiedenmann B., FALCONI , MASSIMO, Erasmus MC other, U., Pape, A., Perren, B., Niederle, D., Gro, T., Gre, F., Costa, R., Arnold, T., Denecke, U., Plöckinger, R., Salazar, A., Grossman, B. C., Conference Anlauf M, Arnold, R, Bartsch, D, Baudin, E, Baum, R, Brandi, Ml, Cadiot, G, Costa, F, Caplin, M, Couvelard, A, de Herder, W, Delle Fave, G, Denecke, T, Eriksson, B, Falconi, Massimo, Gress, T, Gross, D, Grossman, A, Jensen, R, Kaltsas, G, Kelestimur, F, Kianmanesh, R, Klöppel, G, Klose, Kj, Knigge, U, Komminoth, P, Kos Kudla, B, Krenning, E, Kwekkeboom, D, Lopes, Jm, Niederle, B, Nilsson, O, Öberg, K, O'Connor, J, O'Toole, D, Pape, Uf, Papotti, M, Pascher, A, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Salazar, R, Sasano, H, Sauvanet, A, Scoazec, Jy, Steinmüller, T, Sundin, A, Taal, B, Tomassetti, P, Van Cutsem, E, Vullierme, Mp, and Wiedenmann, B.

Subjects
medicine.medical_specialty, Endocrine and Autonomic Systems, business.industry, Endocrinology, Diabetes and Metabolism, General surgery, University hospital, Appendix, Appendiceal neoplasms, Neuroendocrine Tumors, Cellular and Molecular Neuroscience, Jejunum, Endocrinology, medicine.anatomical_structure, Appendiceal Neoplasms, Ileum, Internal medicine, Intestinal Neoplasms, neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas, medicine, Humans, business
Abstract

a Division of Hepatology and Gastroenterology, Department of Internal Medicine, Campus Virchow-Klinikum, Charite-Universitatsmedizin Berlin, Berlin , Germany; b Department of Pathology, Universitatsspital, Zurich , Switzerland; c Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna , Austria; d Department of Endocrinology and Metabolism, Hadassah University Hospital, Jerusalem , Israel; e Department of Internal Medicine, Philipps University, Marburg , Germany; f Hopital Sirio Libanes, Centro de Oncologia, Sao Paulo , Brazil; g Department of Radiology, Campus Virchow-Klinikum, Charite, University Medicine Berlin, Berlin , Germany; h Department of Oncology, Institut Catala d’Oncologia (IDIBELL), Barcelona , Spain; i Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford , UK

Published
2012
Full Text
View/download PDF

7. Recommendations for management of patients with neuroendocrine liver metastases

Author

Andrea, Frilling, Modlin, Irvin M., Mark, Kidd, Christopher, Russell, Stefan, Breitenstein, Riad, Salem, Dik, Kwekkeboom, Wan yee Lau, Catherine, Klersy, Valerie, Vilgrain, Brian, Davidson, Mark, Siegler, Martyn, Caplin, Enrico, Solcia, Richard, Schilsky, Adam, R, Akerstrom, G, Belghiti, J, Breitenstein, S, Clavien, Pa, Frilling, A, Gustafsson, B, Krenning, E, Modlin, Im, Norton, J, Öberg, K, Poston, G, Ruszniewski, P, Tait, P, Toogood, G, Russell, C, Bouvier, C, Jarecki, A, Klersy, C, Lau, Wj, Siegler, M, Rindi, G, Kidd, M, Vilgrain, V, Baum, Rp, Heaton, N, Garden, J, Fan, St, Van Gulik, T, Sipperstein, A, Kwekkeboom, D, Caplin, M, Lawrence, B, de Herder, W, Ito, T, Perren, A, Davidson, B, Klimstra, Ds, Kloppel, G, Scarpa, A, Meyer, T, Knuth, A, Chen, H, Van Cutsem, E, Pavel, Me, Kos Kudla, B, Conlon, K, Imamura, M, Kaltsas, G, Broering, D, Wiedenmann, B, Al Nahhas, A, Lodge, P, Cosimelli, M, Grazi, G, Tang, Lh, Salazar, R, Grossman, Ab, Dejong, C, Gores, G, Nagorney, Dm, Mazzaferro, V, Jensen, R, Lesurtel, M, Falconi, M, Hellmann, P, O'Toole, D, Olauson, M, Le Treut, Y, Burroughs, Ak, Valle, J, Kianmanesch, R, Sowa Staszczak, A, Milicevic, M, Lencioni, RICCARDO ANTONIO, Ramage, J, Sangro, B, Kennedy, A, Bester, L, Salem, R, Sharma, R, Parks, R, Bodei, L, Muller Brand, J, Kvols, L, Manas, D, Ramos, J, Wasan, H., Frilling, Andrea, Modlin Irvin, M., Kidd, Mark, Russell, Christopher, Breitenstein, Stefan, Salem, Riad, Kwekkeboom, Dik, Lau Wan, Yee, Klersy, Catherine, Vilgrain, Valerie, Davidson, Brian, Siegler, Mark, Caplin, Martyn, Solcia, Enrico, Schilsky, Richard, Falconi, Massimo, Andrea, Frilling, Modlin, Irvin M., Mark, Kidd, Christopher, Russell, Stefan, Breitenstein, Riad, Salem, Dik, Kwekkeboom, Wan-yee, Lau, Catherine, Klersy, Valerie, Vilgrain, Brian, Davidson, Mark, Siegler, Martyn, Caplin, Enrico, Solcia, Richard, Schilsky, for the Working Group on Neuroendocrine Liver Metastases,, Grazi, G., Radiology & Nuclear Medicine, and Internal Medicine

Subjects
medicine.medical_specialty, Biopsy, MEDLINE, clinical practice guidelines, hepatic metastases, prognostic factors, surgical management, Neuroendocrine tumors, surgical management, Systemic therapy, NO, medicine, Hepatectomy, Humans, hepatic metastases, Intensive care medicine, medicine.diagnostic_test, business.industry, Liver Neoplasms, prognostic factors, Interventional radiology, medicine.disease, Neoplastic Cells, Circulating, Neoadjuvant Therapy, Surgery, Clinical Practice, Neuroendocrine Tumors, Oncology, Genomic information, business, Working group, clinical practice guidelines
Abstract

Many management strategies exist for neuroendocrine liver metastases. These strategies range from surgery to ablation with various interventional radiology procedures, and include both regional and systemic therapy with diverse biological, cytotoxic, or targeted agents. A paucity of biological, molecular, and genomic information and an absence of data from rigorous trials limit the validity of many publications detailing management. This Review represents the views from an international conference, for which 15 expert working groups prepared evidence-based assessments addressing specific questions, and from which an independent jury derived final recommendations. The aim of the conference was to review the existing approaches to neuroendocrine liver metastases, assess the evidence on which management decisions were based, develop internationally acceptable recommendations for clinical practice (when evidence was available), and make recommendations for clinical and research endeavours. This report represents the final clinical statements and proposals for future research. © 2014 Elsevier Ltd.

Published
2014
Full Text
View/download PDF

8. ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation

Author

Knigge, U, Capdevila, J, Bartsch, D K, Baudin, E, Falkerby, J, Kianmanesh, R, Kos-Kudla, B, Niederle, B, Nieveen van Dijkum, E, O'Toole, D, Pascher, A, Reed, N, Sundin, A, Vullierme, M-P, Ferone, D, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA -Cancer Center Amsterdam, Other Research, and Surgery

Subjects
medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, MEDLINE, TNM staging, 030209 endocrinology & metabolism, 610 Medicine & health, 5-Hydroxyindoleacetic acid, Neuron specific enolase, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Endocrinology, Documentation, Neuroendocrine tumor, Internal medicine, medicine, Neuroendocrine carcinoma, Neuroendocrine neoplasm, Follow up, Chromogranin A, NT-pro-brain natriuretic peptide, Functional imaging, Somatostatin receptor imaging, Endocrine and Autonomic Systems, business.industry, 030220 oncology & carcinogenesis, TNM Staging, 570 Life sciences, biology, business
Abstract

ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms (NEN) concerning follow-up and documentation are considered in this review. The documentation of patients with NEN should include the most relevant data characterizing an individual patient from the first contact with his/her physician/hospital until his/her last presentation during follow-up. It is advocated that follow-up occurs in specialized NEN centers with regular NEN tumor boards with expert panels. The follow-up should be in accordance with the ENETS consensus guidelines from 2011 and 2016, the present and coming WHO classification and ENETS/UICC recommendations for TNM staging. The recommendations for follow-up in patients with thymic, bronchopulmonary and gastroenteropancreatic NEN are given in Table 1. However, it should be stressed that evidence-based studies for follow-up are largely missing. (C) 2017 S. Karger AG, Basel

Published
2017
Full Text
View/download PDF

9. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors:Echocardiography

Author

Plöckinger, U., Gustafsson, B., Ivan, D., Szpak, W., Davar, J., Åkerstrom, G., Annibale, B., Arnold, R., Bajetta, E., Barkmanova, J., Chen, Y. J., Costa, F., Couvelard, A., Herder, W. D., Fave, G. D., Eriksson, B., Falconi, M., Ferone, D., Gross, D., Grossman, A., Hyrdel, R., Kaltsas, G., Kianmanesh, R., Klöppel, G., Knigge, U. P., Komminoth, P., Kos Kudla, B., Kwekkeboom, D., Lebtahi, R., Lewington, V., Mcnicol, A. M., Mitry, E., Nilsson, O., Öberg, K., O'Connor, J., O'Toole, D., Pape, U. F., Papotti, M., Pavel, M., Perren, A., Platania, M., Rindi, G., Ruszniewski, P., Salazar, R., Scarpa, Aldo, Scheidhauer, K., Scoazec, J. Y., Sundin, A., Taal, B., Vitek, P., Vullierme, M. P., and Wiedenmann, B.

Subjects
medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Carcinoid tumors, MEDLINE, Carcinoid Heart Disease, carcinoid syndrome, Diagnostic accuracy, Disease, Neuroendocrine tumors, Cellular and Molecular Neuroscience, Endocrinology, cancer diagnosis, Internal medicine, Humans, echocardiography, Medicine, human, medical society, conference paper, medical documentation, Endocrine and Autonomic Systems, business.industry, practice guideline, Medical practice, diagnostic accuracy, medical practice, neuroendocrine tumor, patient information, priority journal, medicine.disease, Medical documents, Neuroendocrine Tumors, business, Carcinoid syndrome
Abstract

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors : echocardiography.

Published
2009
Full Text
View/download PDF

10. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes

Author

Jensen, R. T., Cadiot, G., Brandi, M. L., W. W., De, Kaltsas, G., Komminoth, P., Scoazec, J., Salazar, R., Sauvanet, A., Kianmanesh, R., Conference Anlauf M, B. C., Arnold, R, Bartsch, D, Baudin, E, Baum, R, Brandi, Ml, Cadiot, G, Costa, F, Caplin, M, Couvelard, A, de Herder, W, Delle Fave, G, Denecke, T, Eriksson, B, Falconi, Massimo, Gress, T, Gross, D, Grossman, A, Jensen, R, Kaltsas, G, Kelestimur, F, Kianmanesh, R, Klöppel, G, Klose, Kj, Knigge, U, Komminoth, P, Kos Kudla, B, Krenning, E, Kwekkeboom, D, Lopes, Jm, Niederle, B, Nilsson, O, Öberg, K, O'Connor, J, O'Toole, D, Pape, Uf, Papotti, M, Pascher, A, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Salazar, R, Sasano, H, Sauvanet, A, Scoazec, Jy, Steinmüller, T, Sundin, A, Taal, B, Tomassetti, P, Van Cutsem, E, Vullierme, Mp, Wiedenmann, B., R. T., Jensen, G., Cadiot, M. L., Brandi, W. W., De, G., Kaltsa, P., Komminoth, J., Scoazec, R., Salazar, A., Sauvanet, R., Kianmanesh, B. C., Conference Anlauf M, Arnold, R, Bartsch, D, Baudin, E, Baum, R, Brandi, Ml, Cadiot, G, Costa, F, Caplin, M, Couvelard, A, de Herder, W, Delle Fave, G, Denecke, T, Eriksson, B, Falconi, Massimo, Gress, T, Gross, D, Grossman, A, Jensen, R, Kaltsas, G, Kelestimur, F, Kianmanesh, R, Klöppel, G, Klose, Kj, Knigge, U, Komminoth, P, Kos Kudla, B, Krenning, E, Kwekkeboom, D, Lopes, Jm, Niederle, B, Nilsson, O, Öberg, K, O'Connor, J, O'Toole, D, Pape, Uf, Papotti, M, Pascher, A, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Salazar, R, Sasano, H, Sauvanet, A, Scoazec, Jy, Steinmüller, T, Sundin, A, Taal, B, Tomassetti, P, Van Cutsem, E, Vullierme, Mp, Wiedenmann, B., and Internal Medicine

Subjects
ENETS Consensus Guidelines, medicine.medical_specialty, Pathology, Endocrinology, Diabetes and Metabolism, ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes, Hypoglycemia, Neuroendocrine tumors, Cellular and Molecular Neuroscience, Endocrinology, Internal medicine, medicine, Humans, Pancreatic polypeptide, MEN1, Multiple endocrine neoplasia, biology, Endocrine and Autonomic Systems, business.industry, Chromogranin A, medicine.disease, Pancreatic Neoplasms, Neuroendocrine Tumors, medicine.anatomical_structure, biology.protein, Pancreas, business, Carcinoid syndrome
Abstract

Pancreatic endocrine tumors (p-NETs) include both pancreatic neuroendocrine tumors (p-NETs) associated with a functional syndrome (functional p-NETs) or those associated with no distinct clinical syndrome (non-functional p-NETs) [1,2,3,4]. Non-functional p-NETs frequently secrete pancreatic polypeptide, chromogranin A, neuron-specific enolase, human chorionic gonadotrophin subunits, calcitonin, neurotensin or other peptides, but they do not usually produce specific symptoms and thus are considered clinically to be non-functional tumors [2,3,5,6,7]. Only the functional p-NETs will be considered in this section. The two most common functional p-NETs (gastrinomas, insulinomas) are considered separately, whereas the other well-described and possible rare functional p-NETs are considered together as a group called rare functional p-NETs (RFTs) (table ​(table1)1) [1,2,3,4]. Table 1 Functional pancreatic endocrine tumor (PET) syndromes Gastrinomas are neuroendocrine neoplasms, usually located in the duodenum or pancreas, that secrete gastrin and cause a clinical syndrome known as Zollinger-Ellison syndrome (ZES). ZES is characterized by gastric acid hypersecretion resulting in severe peptic disease (peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD)) [8,9,10]. In this section, ZES due to both duodenal and pancreatic gastrinomas will be covered together because clinically they are similar [8,10]. Specific points related to gastrinomas associated with the genetic syndrome of Multiple Endocrine Neoplasia type 1 (MEN1) (25% of cases) will also be mentioned [11,12]. Insulinomas are neuroendocrine neoplasms located in the pancreas that secrete insulin, which causes a distinct syndrome characterized by symptoms due to hypoglycemia [2,13,14,15]. The symptoms are typically associated with fasting and the majority of patients have symptoms secondary to hypoglycemic central nervous system (CNS) effects (headaches, confusion, visual disturbances, etc.) or due to catecholamine excess secondary to hypoglycemia (sweating, tremor, palpitations, etc.) [2,3,13,14,15]. RFTs can occur in the pancreas or in other locations (VIPomas, somatostatinomas, GRHomas, ACTHomas, p-NETs causing carcinoid syndrome or hypercalcemia (PTHrp-omas)) (table ​(table1)1) [1,2,3,4,5,7]. Each of the established RFT syndromes is associated with a distinct clinical syndrome reflecting the actions of the ectopically secreted hormone. Other RFTs are listed as causing a possible specific syndrome either because there are too few cases or there is disagreement about whether the described features are actually a distinct syndrome (table ​(table1)1) [1,2,3,4,5,7].

Published
2012

11. ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Colorectal Neuroendocrine Neoplasms

Author

M. Caplin, A. Sundin, O. Nillson, R. P. Baum, K. J. Klose, F. Kelestimur, U. Plöckinger, M. Papotti, R. Salazar, A. Pascher, B. C. Conference Anlauf M, Arnold R, Bartsch D, Baudin E, Baum R, Brandi ML, Cadiot G, Costa F, Caplin M, Couvelard A, de Herder W, Delle Fave G, Denecke T, Eriksson B, Gress T, Gross D, Grossman A, Jensen R, Kaltsas G, Kelestimur F, Kianmanesh R, Klöppel G, Klose KJ, Knigge U, Komminoth P, Kos Kudla B, Krenning E, Kwekkeboom D, Lopes JM, Niederle B, Nilsson O, Öberg K, O'Connor J, O'Toole D, Pape UF, Papotti M, Pascher A, Pavel M, Perren A, Plöckinger U, Rindi G, Ruszniewski P, Salazar R, Sasano H, Sauvanet A, Scoazec JY, Steinmüller T, Sundin A, Taal B, Tomassetti P, Van Cutsem E, Vullierme MP, Wiedenmann B., FALCONI , MASSIMO, M., Caplin, A., Sundin, O., Nillson, R. P., Baum, K. J., Klose, F., Kelestimur, U., Plöckinger, M., Papotti, R., Salazar, A., Pascher, B. C., Conference Anlauf M, Arnold, R, Bartsch, D, Baudin, E, Baum, R, Brandi, Ml, Cadiot, G, Costa, F, Caplin, M, Couvelard, A, de Herder, W, Delle Fave, G, Denecke, T, Eriksson, B, Falconi, Massimo, Gress, T, Gross, D, Grossman, A, Jensen, R, Kaltsas, G, Kelestimur, F, Kianmanesh, R, Klöppel, G, Klose, Kj, Knigge, U, Komminoth, P, Kos Kudla, B, Krenning, E, Kwekkeboom, D, Lopes, Jm, Niederle, B, Nilsson, O, Öberg, K, O'Connor, J, O'Toole, D, Pape, Uf, Papotti, M, Pascher, A, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Salazar, R, Sasano, H, Sauvanet, A, Scoazec, Jy, Steinmüller, T, Sundin, A, Taal, B, Tomassetti, P, Van Cutsem, E, Vullierme, Mp, and Wiedenmann, B.

Subjects
medicine.medical_specialty, Endocrine and Autonomic Systems, business.industry, Endocrinology, Diabetes and Metabolism, ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms, stomatognathic diseases, Cellular and Molecular Neuroscience, Neuroendocrine Tumors, Endocrinology, Internal medicine, medicine, Humans, business, Colorectal Neoplasms
Abstract

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms : colorectal neuroendocrine neoplasms

Published
2012

12. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs

Author

Kwekkeboom, D. J., Krenning, E. P., Lebtahi, R., Komminoth, P., Kos-Kudla, B., De Herder, W. W., Plockinger, U., Akerstrom, G., Annibale, B., Arnold, R., Bajetta, E., Barkmanova, J., Chen, Y. -J., Costa, F., Couvelard, A., Davar, J., Delle Fave, G., Eriksson, B., Falconi, M., Ferone, D., Gross, D., Grossman, A., Gustafsson, B., Hyrdel, R., Ivan, D., Kaltsas, G., Kianmanesh, R., Kloppel, G., Knigge, U. -P., Lewington, V., Mcnicol, A. M., Mitry, E., Nilsson, O., Oberg, K., O'Connor, J., O'Toole, D., Pape, U. -F., Papotti, M., Pavel, M., Perren, A., Platania, M., Rindi, G., Ruszniewski, P., Salazar, R., Scarpa, A., Scheidhauer, K., Scoazec, J. -Y., Sundin, A., Szpak, W., Taal, B., Vitek, P., Vullierme, M. -P., Wiedenmann, B., Radiology & Nuclear Medicine, and Internal Medicine

Subjects
Peptide receptor, Endocrinology, Diabetes and Metabolism, Treatment outcome, 1 4 7 10 tetraacetic acid, Neuroendocrine tumors, Endocrinology, Receptors, comparative study, conference paper, peptide receptor radionuclide therapy, 1 4 7 10 tetraazacyclododecane, GEPNET, Carcinoids, clinical trial, yttrium 90, peptide, unclassified drug, drug dose comparison, Somatostatin, priority journal, neuroendocrine tumor, medicine.medical_specialty, Receptors, Peptide, Radiolabeled somatostatin analogues, lutetium 177, octreother, octreotide[3 tyrosine], pentetreotide in 111, radioisotope, somatostatin derivative, cancer radiotherapy, drug dose escalation, human, multiple cycle treatment, practice guideline, treatment duration, treatment outcome, Cellular and Molecular Neuroscience, Internal medicine, medicine, Humans, Radioisotopes, Radiotherapy, Endocrine and Autonomic Systems, business.industry, Guideline, Neuroendocrine Tumors, medicine.disease, Clinical trial, Cancer Radiotherapy, Radionuclide therapy, business
Abstract

The purpose of this guideline is to assist physicians caring for patients with neuroendocrine tumors in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT), and in defining the minimum requirements for PRRT. This guideline also makes recommendations on what minimal patient, tumor, and treatment outcome characteristics should be reported for PRRT in order to make comparisons between studies possible. It is not this guideline's aim to give specific recommendations on the use of specific radiolabeled somatostatin analogs for PRRT because different analogs are being used, and their availability depends on national law and local permissions. Copyright (C) 2009 S. Karger AG, Basel

Published
2009

13. Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms

Author

Baudin, Eric, Hayes, Aimee R., Scoazec, Jean-Yves, Filosso, Pier Luigi, Lim, Eric, Kaltsas, Gregory, Frilling, Andrea, Chen, Jie, Kos-Kudla, Beata, Gorbunova, Vera, Wiedenmann, Bertram, van Dijkum, Els Nieveen, Cwikla, Jaroslaw B., Falkerby, Jenny, Valle, Juan W., Kulke, Matthew H., Caplin, Martyn E., Detlef, Bartsch, Rudolf, Arnold, Eric, Baudin, Lisa, Bodei, Ivan, Borbath, Jaume, Capdevila, Martyn, Caplin, Jie, Chen, Frederico, Costa, Anne, Couvelard, Jaroslaw, Cwikla B., Philippa, Davies, de Herder, Wouter W., Massimo, Falconi, Jenny, Falkerby, Nicola, Fazio, Diego, Ferone, Andrea, Frilling, Rocio, Garcia-Carbonero, Simona, Glasberg, Vera, Gorbunova, Ashley, Grossman, Dieter, Hoech, Robert, Jensen, Gregory, Kaltsas, Guenter, Kloeppel, Peter, Knigge Ulrich, Beata, Kos-Kudla, Guenter, Krejs J., Eric, Krenning, Matthew, Kulke, Steven, Lamberts W. J., van Elisabeth, Nieveen Dijkum, Juan Manuel, O'Connor, Dermot, O'Toole, Ulrich-Frank, Pape, Stefano, Partelli, Ellen, Pavel Marianne, Peeters, Marc, John, Ramage, Simon, Reed Nicholas, Guido, Rindi, Anja, Rinke, Philippe, Ruszniewski, Halfdan, Sorbye, Anders, Sundin, Jean-Yves, Scoazec, Babs, Taal G., Eva, Tiensuu Janson, Christos, Toumpanakis, Juan, Valle, Marie-Pierre, Vullierme, Staffan, Welin, Bertram, Wiedenmann, ENETS 2016 Munich Advisory Board, Internal Medicine, Baudin, E, Hayes, A R, Scoazec, J-Y, Filosso, Pl, Lim, E, Kaltsas, G, Frilling, A, Chen, J, Kos-Kudla, B, Gorbunova, V, Wiedenmann, B, Nieveen, Van Dijkum E, Cwikla, J B, Falkerby, J, Valle, J W, Kulke, M H, Caplin, M E, on behalf The ENETS 2016 Munich Advisory Board, Participant, Partelli, S, Falconi, M, and Dr. Heinz-Horst Deichmann Stiftung

Subjects
Oncology, Biomedical Research, Lung Neoplasms, SOMATOSTATIN RECEPTORS, Endocrinology, Diabetes and Metabolism, CHROMOGRANIN-A, 030218 nuclear medicine & medical imaging, 0302 clinical medicine, Endocrinology, PROGNOSTIC-FACTORS, PROLIFERATIVE INDEX, Prognosis, Neuroendocrine Tumors, Neuroendocrine Tumors/classification, CUSHINGS-SYNDROME, Tumour classification, ENETS 2016 Munich Advisory Board Participants, Life Sciences & Biomedicine, medicine.medical_specialty, Carcinoid Tumor/classification, 030209 endocrinology & metabolism, Carcinoid Tumor, ENETS CONSENSUS GUIDELINES, 03 medical and health sciences, Cellular and Molecular Neuroscience, Endocrinology & Metabolism, Biomedical Research/trends, Internal medicine, Pulmonary carcinoids, medicine, Humans, EUROPEAN ASSOCIATION, Science & Technology, Endocrine and Autonomic Systems, CLINICAL-FEATURES, Bronchial carcinoid tumour, Neurosciences, 1103 Clinical Sciences, ECTOPIC ACTH SYNDROME, Lung Neoplasms/classification, Clinical trial, NET, Neuroendocrine neoplasm, Bronchial carcinoid tumours, Ectopic ACTH syndrome, Neuroendocrine neoplasms, Neurosciences & Neurology, RECEPTOR RADIONUCLIDE THERAPY, Human medicine, Management principles, Atypical carcinoid, 1109 Neurosciences
Abstract

Pulmonary carcinoids (PCs) display the common features of all well-differentiated neuroendocrine neoplasms (NEN) and are classified as low- and intermediate-grade malignant tumours (i.e., typical and atypical carcinoid, respectively). There is a paucity of randomised studies dedicated to advanced PCs and management principles are drawn from the larger gastroenteropancreatic NEN experience. There is growing evidence that NEN anatomic subgroups have different biology and different responses to treatment and, therefore, should be investigated as separate entities in clinical trials. In this review, we discuss the existing evidence and limitations of tumour classification, diagnostics and staging, prognostication, and treatment in the setting of PC, with focus on unmet medical needs and directions for the future.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results